Two Strikes and Monoclonal Antibodies Are Out for Early Parkinson's? - Medpage Today

Failure of two agents in two phase II trials could spell the end for one avenue of treatment

Similarly designed phase II trials of two investigational alpha-synuclein targeted biologics dashed hopes for disease-modifying monoclonal antibody drugs in early-stage Parkinson's disease. In the S… [+4343 chars]

full article...